相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Moshe Talpaz et al.
LEUKEMIA (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Brett King et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
Zhenpeng Dai et al.
JCI INSIGHT (2021)
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19
Nathan D. Pfeifer et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19
Dave Singh et al.
EUROPEAN RESPIRATORY JOURNAL (2021)
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis
Yuan Yin et al.
BIOORGANIC CHEMISTRY (2020)
Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders
Pengfei Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael F. Robinson et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Robert Zeiser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
Andrea Rubbert-Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Hua Xu et al.
ACS CHEMICAL BIOLOGY (2019)
Peficitinib: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Jun Dai et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
Xingrui He et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis
Song Shan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
Desiree van der Heijde et al.
LANCET (2019)
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1
Jason G. Kettle et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2
Jason G. Kettle et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-(2s,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-y1)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
Atli Thorarensen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
Peter Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
Fiona Elwood et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
The emerging safety profile of JAK inhibitors in rheumatic disease
Kevin L. Winthrop
NATURE REVIEWS RHEUMATOLOGY (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mechanisms and consequences of Jak-STAT signaling in the immune system
Alejandro V. Villarino et al.
NATURE IMMUNOLOGY (2017)
VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
Jean-Baptiste Telliez et al.
ACS CHEMICAL BIOLOGY (2016)
Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
Geoffrey A. Smith et al.
NATURE CHEMICAL BIOLOGY (2016)
Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases
Ana Karina Alves de Medeiros et al.
PLOS ONE (2016)
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Roy M. Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
Eric R. Goedken et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
James D. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
Eun Bong Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
Qingsong Liu et al.
CHEMISTRY & BIOLOGY (2013)
Inborn Errors of Human JAKs and STATs
Jean-Laurent Casanova et al.
IMMUNITY (2012)
Ruxolitinib
Ruben A. Mesa et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
Ana L. Basquiera et al.
HEMATOLOGY (2009)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Regulation of JAK-STAT signalling in the immune system
K Shuai et al.
NATURE REVIEWS IMMUNOLOGY (2003)
分享论文
